Genprex (FRA:2DE1) Float Percentage Of Total Shares Outstanding: 100.78% (As of Jul. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2DE1 Genprex Inc FRA:2DE1
33 GF Score
Price €3.96
! 1 Warning Sign
View Full Analysis

What is Genprex Float Percentage Of Total Shares Outstanding?

Genprex FRA:2DE1 33 Float Percentage Of Total Shares Outstanding is 100.78% as of Jul. 24, 2026. GuruFocus rates FRA:2DE1 with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Genprex's float shares is 0.50 Mil. Genprex's total shares outstanding is 0.50 Mil. Genprex's float percentage of total shares outstanding is 100.78%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Genprex's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Genprex's Institutional Ownership is 1.50%.

FRA:2DE1
33GF Score
Genprex Inc FRA:2DE1
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genprex Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Genprex's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.50/0.50
=100.78%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 100.78% mean?
Genprex (FRA:2DE1) has a Float Percentage Of Total Shares Outstanding of 100.78% as of Jul. 24, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Genprex and its competitors.
Is Genprex's Float Percentage Of Total Shares Outstanding too high?
Genprex's current Float Percentage Of Total Shares Outstanding is 100.78%. Overall, Genprex has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Genprex's Float Percentage Of Total Shares Outstanding compare to MLEC and LIMN?
Genprex's Float Percentage Of Total Shares Outstanding of 100.78% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Genprex and its competitors. Genprex's current Float Percentage Of Total Shares Outstanding is 100.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genprex stock overvalued right now?
Genprex (FRA:2DE1) has a current Float Percentage Of Total Shares Outstanding of 100.78%. The current Float Percentage Of Total Shares Outstanding is 100.78%. Genprex's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Genprex (FRA:2DE1), the current Float Percentage Of Total Shares Outstanding is 100.78% as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genprex Business Description

Other Exchanges GNPX:USA0A8I:UK
Address 3300 Bee Cave Road, Suite 650-227, Austin, TX, USA, 78746
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
33GF Score

Get the complete analysis for FRA:2DE1

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.96
Price